Fidelity Investments’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Fidelity Investments’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5	Closed	–	–	5623
2022 Q1	$0	Sell	5 -31	-86%	-$106	﹤0.01%	5623
2021 Q4	$0	Sell	36 -59	-62%	-$567	﹤0.01%	5079
2021 Q3	$1K	Sell	95 -1,135	-92%	-$13.4K	﹤0.01%	4230
2021 Q2	$16K	Sell	1,230 -152,660	-99%	-$2.04M	﹤0.01%	3441
2021 Q1	$2.37M	Buy	+153,890	New	+$3.63M	﹤0.01%	2438

Other funds holding GRCL

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments's GRCL Position: Q2 2022 in Review

Fidelity Investments sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q2 2022, closing a stake of 5 shares.

Fidelity Investments first reported a position in GRCL in Q1 2021 and held it in 5 quarters. The position peaked at $2.37M in Q1 2021. 32 funds tracked by Wall St. Rank hold GRCL as of Q2 2022.

Fidelity Investments reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q2 2022 after selling out during the quarter.
Fidelity Investments sold 5 Gracell Biotechnologies Inc. American Depositary Shares shares in Q2 2022.
Fidelity Investments first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2021 and held it in 5 quarters.
Fidelity Investments's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $2.37M in Q1 2021.
32 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q2 2022.

Based on Fidelity Investments's 13F filing for Q2 2022, filed 12 Aug 2022.